AAOS Now / Issue
Clinical use of biologics to treat orthopaedic problems has greatly outpaced the evidence. This rise is primarily due to widespread use of “minimally manipulated” autologous therapies that are either blood products or have been interpreted as falling within the Public Health Service Act Section 361 pathway, which does not require premarket approval from the U.S. Food and Drug Administration (FDA).
Some AAOS Now articles are available only to AAOS members. Please log in to access this article.
Not a member? Become a member.